Accumetrics recently appointed PAI as the exclusive distributor in the Philippines of VerifyNow system- platelet function test to determine patient response to anti-platelet therapies -P2Y12, Aspirin and GP IIb/IIIa.
Platelet Function Testing from Accumetrics
Posted: 17 February 2012 Category: latest news
PAI got approval from Accumetrics as official distributor of the VerifyNow Intrument and VerifyNow Aspirin, P2Y12 and GP llb/lla Tests here in the Philippines.
Proven in over 200 peer-reviewed studies, the VerifyNow System, which includes a rapid, easy-to-use instrument and individual test cartridges, helps physicians assess platelet reactivity in the presence of aspirin, P2Y12 inhibitors (such as Plavix® and Effient®), and GP IIb/IIIa inhibitors (including ReoPro® and Integrilin®).
Antiplatelet Therapy Just Got Personal.
Approximately 81 million Americans have one or more types of cardiovascular disease and an additional 15 million people suffer from neurovascular disease worldwide. Antiplatelet agents (such as aspirin, clopidogrel and prasugrel) are widely prescribed in patients with acute coronary syndrome (ACS) to prevent heart attacks, strokes and other potentially life-threatening cardiovascular events:
- 50 million Americans are on chronic aspirin therapy
-
Over 29 million patients are on Plavix® and over 6.5 million new prescriptions are written annually for Plavix,
making it the second largest selling drug worldwide.
Studies show that patients Do Not respond equally to antiplatelet therapy.
- Up to 1/3 of patients on antiplatelet medications may not respond adequately to antiplatelet medications.
- Patients who are not responding adequately to their antiplatelet medications may be at significantly higher risk of ischemic events and death.
Therefore, early assessment of your patient’s platelet response to antiplatelet therapy is crucial to improving patient care.
Assessing how patients respond to their antiplatelet therapy should be easy.
it is.
References available upon request